作者
Muthiah Vaduganathan, Kieran F Docherty, Brian L Claggett, Pardeep S Jhund, Rudolf A de Boer, Adrian F Hernandez, Silvio E Inzucchi, Mikhail N Kosiborod, Carolyn SP Lam, Felipe Martinez, Sanjiv J Shah, Akshay S Desai, John JV McMurray, Scott D Solomon
发表日期
2022/9/3
期刊
The Lancet
卷号
400
期号
10354
页码范围
757-767
出版商
Elsevier
简介
Background
SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction.
Methods
We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects …
学术搜索中的文章
M Vaduganathan, KF Docherty, BL Claggett, PS Jhund… - The Lancet, 2022